Status:
ACTIVE_NOT_RECRUITING
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Lead Sponsor:
AbbVie
Conditions:
Parkinson's Disease (PD)
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremor...
Eligibility Criteria
Inclusion
- Participants who have Parkinson's Disease and who have successfully completed the parent study M15-741.
- Participants willing and able to comply with procedures required in the protocol.
Exclusion
- \- Participants, if judged by the investigator to be unsuitable candidates to continue to receive ABBV-951 for any reason.
Key Trial Info
Start Date :
June 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04379050
Start Date
June 8 2020
End Date
April 1 2026
Last Update
August 5 2025
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham - Main /ID# 215597
Birmingham, Alabama, United States, 35233
2
Banner Sun Health Research Institute /ID# 215579
Sun City, Arizona, United States, 85351
3
University of Colorado Hospital /ID# 215625
Aurora, Colorado, United States, 80045
4
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412
Boca Raton, Florida, United States, 33486